Novo Nordisk(NVO)2024-05-01 16:00Sales Performance - Sales increased by 22% in Danish kroner and 24% at constant exchange rates (CER) to DKK 65.3 billion in Q1 2024[3] - Total sales grew by 22% in Danish kroner and 24% at CER to DKK 65,349 million, driven by Diabetes care sales growth of 24% (CER) and Obesity care sales growth of 42% (CER)[15] - Net sales increased by 22% to DKK 65,349 million in Q1 2024 compared to Q1 2023[110] - Net sales increased to DKK 65,349 million in Q1 2024, up from DKK 53,367 million in Q1 2023, representing a 22.4% growth[111] - Net sales at CER grew 24% to DKK 66,307 million, compared to DKK 53,367 million in Q1 2023[121] Operating Profit and Margins - Operating profit grew by 27% in Danish kroner and 30% at CER to DKK 31.8 billion[3] - Operating profit increased by 27% in Danish kroner and 30% at CER to DKK 31,846 million, driven by sales growth, while net profit increased by 28% to DKK 25,407 million[58] - Operating profit (EBIT) grew by 27% to DKK 31,846 million, with an operating margin of 48.7% in Q1 2024[110] - Operating profit for Diabetes and Obesity care segment improved to DKK 31,218 million in Q1 2024, with an operating margin of 51.2%, up from 49.5% in Q1 2023[111] - Operating profit at CER increased 30% to DKK 32,594 million, up from DKK 25,007 million in Q1 2023[121] - Operating profit (EBIT) increased by 27% to DKK 31,846 million in Q1 2024 from DKK 25,007 million in Q1 2023[122] Diabetes and Obesity Care Sales - Diabetes and Obesity care sales rose by 25% in Danish kroner to DKK 61.0 billion, with Obesity care growing by 41% to DKK 11.0 billion[3] - GLP-1 diabetes sales increased by 30% in Danish kroner (32% at CER), while Rare disease sales decreased by 4% (3% at CER)[3] - Obesity care sales increased by 42% at CER to DKK 11.0 billion, with a target of more than DKK 25 billion in sales by 2025[9] - GLP-1-based products for type 2 diabetes (Rybelsus, Ozempic, and Victoza) increased by 30% in Danish kroner and 32% at CER to DKK 34,982 million, with Ozempic sales growing 42% to DKK 27,810 million[21][23] - Obesity care sales increased by 42% at CER to DKK 11,035 million in Q1 2024, with Wegovy sales growing 107% at CER to DKK 9,377 million[36][37] - Diabetes and Obesity care segment sales grew to DKK 60,965 million in Q1 2024, up from DKK 48,791 million in Q1 2023, a 24.9% increase[111] - Q1 2024 total sales for Diabetes and Obesity care segment reached DKK 60,965 million, a 27% increase at CER[117] - Ozempic® sales grew 43% at CER to DKK 27,810 million, driven by strong performance in North America with a 50% increase[117] - Wegovy® sales surged 107% at CER to DKK 9,377 million, with North America contributing DKK 8,233 million[117] - Total GLP-1 sales increased 32% at CER to DKK 34,982 million, with North America accounting for DKK 24,363 million[117] Regional Sales Performance - North America Operations sales grew by 34% in Danish kroner (35% at CER), driven by US gross-to-net sales adjustments[3] - North America Operations saw GLP-1 diabetes product sales increase by 36% in Danish kroner and 37% at CER, with the US market leading at 53.5% value market share[24] - International Operations GLP-1 sales grew by 20% in Danish kroner and 22% at CER, with a value market share of 70.0%[25] - EMEA sales increased by 18% in Danish kroner and at CER, driven by Ozempic and Rybelsus, with a value market share of 63.3%[26] - Region China sales grew by 4% in Danish kroner and 10% at CER, with a value market share of 78.2%[27] - Rest of World sales increased by 34% in Danish kroner and 38% at CER, with a value market share of 85.6%[28] - North America Operations sales grew by 34% to DKK 39,280 million, with the US contributing DKK 36,782 million[110] - North America Operations contributed 80% of total growth, with sales increasing 35% at CER to DKK 39,280 million[117] - International Operations saw a 11% increase in sales at CER to DKK 26,069 million, with EMEA growing 13%[117] Insulin Sales - Insulin sales increased by 6% in Danish kroner and 9% at CER to DKK 14,365 million, supported by US gross-to-net sales adjustments[29] - Novo Nordisk's global insulin market share is 45.0% in February 2024, down from 46.2% in February 2023, with sales of DKK 14,365 million in Q1 2024, growing at 9% CER[30] - North America Operations insulin sales increased by 23% at CER to DKK 4,243 million, with a US market share of 36.2%[30][31] - International Operations insulin sales grew by 5% at CER to DKK 10,122 million, driven by Region China (14% CER growth) and EMEA (1% CER growth)[30][32] - Region China insulin sales grew 14% at CER to DKK 2,788 million, with a market share of 40.1%, while obesity care sales in China were DKK 25 million, declining 51% at CER[30][37] - Rest of World insulin sales grew 1% at CER to DKK 2,508 million, with a market share of 57.6%, while obesity care sales declined 8% at CER to DKK 615 million[30][37] - Total insulin sales rose 9% at CER to DKK 14,365 million, driven by a 25% increase in the US[117] Rare Disease Sales - Rare disease sales decreased by 3% at CER to DKK 4,384 million in Q1 2024, with North America Operations growing 20% at CER, while International Operations declined 18% at CER[41][42] - Rare disease segment sales decreased to DKK 4,384 million in Q1 2024, down from DKK 4,576 million in Q1 2023, a 4.2% decline[111] - Rare disease segment sales declined 3% at CER to DKK 4,384 million, with Rare blood disorders down 4%[117] Financial Performance - Gross profit rose by 23% to DKK 55,433 million, with a gross margin of 84.8% in Q1 2024[110] - Net profit increased by 28% to DKK 25,407 million in Q1 2024 compared to Q1 2023[110] - Net profit rose to DKK 25,407 million in Q1 2024, compared to DKK 19,814 million in Q1 2023, a 28.2% increase[111] - Net profit rose by 28% to DKK 25,407 million in Q1 2024 from DKK 19,814 million in Q1 2023[122] - EBITDA increased by 30% to DKK 34,760 million in Q1 2024 compared to DKK 26,726 million in Q1 2023[122] - Income taxes increased by 32% to DKK 6,511 million in Q1 2024 compared to DKK 4,923 million in Q1 2023[122] - Financial income surged by 152% to DKK (2,146) million in Q1 2024 from DKK (852) million in Q1 2023[122] - Financial expenses grew by 85% to DKK 2,074 million in Q1 2024 from DKK 1,122 million in Q1 2023[122] - Depreciation, amortisation, and impairment losses rose by 70% to DKK 2,914 million in Q1 2024 from DKK 1,719 million in Q1 2023[122] Cash Flow and Capital Expenditure - Free cash flow in Q1 2024 was DKK 5.0 billion, down from DKK 24.8 billion in Q1 2023, due to lower US gross sales, reduced insulin prices, higher taxes, and increased capital expenditure[61] - Capital expenditure for property, plant, and equipment was DKK 8.5 billion, primarily for API production and fill-finish capacity, with an additional DKK 0.5 billion for intangible assets[62] - Capital expenditure (PP&E) increased by 81% to DKK 8,474 million in Q1 2024[110] - Net cash generated from operating activities was DKK 14,314 million in Q1 2024, compared to DKK 29,814 million in Q1 2023, a 52% decrease[112] - Purchase of property, plant and equipment increased to DKK 8,474 million in Q1 2024, compared to DKK 4,693 million in Q1 2023[112] - Cash and cash equivalents at the end of Q1 2024 stood at DKK 6,324 million, down from DKK 14,392 million at the beginning of the year[112] - Free cash flow decreased to DKK 5,020 million in Q1 2024 from DKK 24,764 million in Q1 2023[124] - Net cash generated from operating activities dropped to DKK 14,314 million in Q1 2024 from DKK 29,814 million in Q1 2023[124] - Net cash used in investing activities was DKK 3,956 million in Q1 2024 compared to DKK (6,647) million in Q1 2023[124] Market Share and Growth Targets - Diabetes value market share increased by 1.8 percentage points to 34.0% (MAT)[9] - Novo Nordisk's global diabetes value market share increased to 34.0% from 32.2%, aiming to reach over one-third market share by 2025[18] - Novo Nordisk expects 2024 sales growth of 19-27% at CER and operating profit growth of 22-30% at CER[4] - Sales growth for 2024 is expected to be 19% to 27% at CER, driven by volume growth of GLP-1-based treatments for Obesity and Diabetes care, with operating profit growth expected at 22% to 30% at CER[68][69] - Capital expenditure for 2024 is expected to be around DKK 45 billion, focusing on expanding manufacturing facilities in Kalundborg, Hillerød, and Chartres, with a low double-digit capital expenditure to sales ratio expected in the coming years[72][73] Product Approvals and Acquisitions - Wegovy was approved in the US for cardiovascular risk reduction, and Awiqli (once-weekly insulin icodec) was recommended for EU approval[4] - The company announced an agreement to acquire three fill-finish sites from Novo Holdings A/S, expected to be completed by end of 2024[4] - Awiqli recommended for approval for the treatment of diabetes by the European regulatory authorities, with final marketing authorisation expected within approximately two months[80] - Novo Nordisk to acquire Cardior Pharmaceuticals GmbH for up to EUR 1.025 billion, including an upfront payment and milestone-based payments[89] Environmental and Social Impact - Total CO2e emissions increased by 32% in Q1 2024 compared to Q1 2023, with Scope 1, 2, and 3 emissions increasing by 6%, 20%, and 32% respectively[92] - The number of patients reached with Novo Nordisk products increased by 10% to 41.8 million in Q1 2024 compared to Q1 2023[94] - The Changing Diabetes in Children programme reached 54,092 children, a 26% increase compared to Q1 2023[95] - Cities for Better Health programme is active in 47 cities across 25 countries, addressing health inequities and prevention of chronic diseases[96] - Novo Nordisk's full-time employees increased by 14% to 66,015 at the end of 2023, driven mainly by Product Supply[97] - 46% of all leaders at Novo Nordisk are women, and 41% of senior leadership positions are held by women as of March 2024, up from 45% and 39% respectively in March 2023[97] Legal and Regulatory Updates - Sales in Russia and Ukraine constituted less than 1% of Novo Nordisk's global sales[99] - Novo Nordisk has entered into settlement agreements with manufacturers regarding generic versions of Victoza and Saxenda, with Teva Pharmaceuticals USA, Inc. licensed to sell an authorized generic version of Victoza in the US market from June 2024[100] - Novo Nordisk does not expect the ANDA filings for generic versions of Ozempic and Wegovy to have a material impact on its financial position, operating profit, or cash flow[100] Earnings and Dividends - Basic earnings per share increased by 30% to DKK 5.70 in Q1 2024[110] - Dividends paid in Q1 2024 amounted to DKK 28,557 million, up from DKK 18,337 million in Q1 2023[115]